Raffaele Ratta

Dr. Raffaele Ratta

Hopital Foch

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2021 in Future Oncology
Verified
Journal Article
Open access
DPDaniel P Petrylak
Daniel P Petrylak
RRRaffaele Ratta
Raffaele Ratta
RGRustem Gafanov
Rustem Gafanov
GFGAETANO FACCHINI
GAETANO FACCHINI
JPJosep M. Piulats
Josep M. Piulats
KFKarim Fizazi
Karim Fizazi
Despite recent advances, treatment options for men with metastatic castration-resistant prostate cancer (mCRPC) progressing after next-generation hormonal agents (NHAs) are limited and provide only...

17 October 2018 in Immunotherapy
Verified
Journal Article
Closed access
MBMelissa Bersanelli
Melissa Bersanelli
DGDiana Giannarelli
Diana Giannarelli
PCPaola Castrignanò
Paola Castrignanò
GFGiuseppe Fornarini
Giuseppe Fornarini
SPStefano Panni
Stefano Panni
Sebastiano ButiSebastiano Buti
Sebastiano Buti
Aim: Considering the unmet need for the counseling of cancer patients treated with immune checkpoint inhibitors (CKI) about influenza vaccination, an explorative study was planned to assess flu vaccine efficacy in this population. Methods: INVIDIa was a retrospective, multicenter study, enrolling consecutive advanced cancer outpatients receiving CKI during the influenza season 2016–2017. Results: Of 300 patients, 79 received flu vaccine. The incidence of influenza syndrome was 24.1% among vaccinated, versus 11.8% of controls; odds ratio: 2.4; 95% CI: 1.23–4.59; p = 0.009. The clinical ineffectiveness of vaccine was more pronounced among elderly: 37.8% among vaccinated patients, versus 6.1% of unvaccinated, odds ratio: 9.28; 95% CI: 2.77–31.14; p < 0.0001. Conclusion: Although influenza vaccine may be clinically ineffective in advanced cancer patients receiving CKI, it seems not to negatively impact the efficacy of anticancer therapy.

4 May 2020 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
RRRaffaele Ratta
Raffaele Ratta
AGAnnalisa Guida
Annalisa Guida
FSFlorian Scotté
Florian Scotté
YNYann Neuzillet
Yann Neuzillet
ATAsmahane Benmaziane Teillet
Asmahane Benmaziane Teillet
PBPhilippe Beuzeboc
Philippe Beuzeboc

1 August 2019 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
GPGiorgia Peverelli
Giorgia Peverelli
ARAlessandra Raimondi
Alessandra Raimondi
RRRaffaele Ratta
Raffaele Ratta
EVElena Verzoni
Elena Verzoni
MBMarco Bregni
Marco Bregni
GPGiuseppe Procopio
Giuseppe Procopio

28 March 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AMAlessia Mennitto
Alessia Mennitto
VHVeronica Huber
Veronica Huber
RRRaffaele Ratta
Raffaele Ratta
PSPierangela Sepe
Pierangela Sepe
FBF. De Braud
F. De Braud
EVElena Verzoni
Elena Verzoni
The frontline treatment options for patients with metastatic renal cell carcinoma (mRCC) are evolving rapidly since the approval of combination immunotherapies by the U.S. Food and Drug Administration (USFDA) and the European Medicines Agency (EMA). In particular, in combination with vascular endothelial growth factor receptor (VEGFR) tyrosine-kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs) have significantly improved the outcome of patients with mRCC compared to TKI monotherapy. Here, we review the preclinical data supporting the combination of ICIs with VEGFR TKIs. The VEGF-signaling inhibition could ideally sustain immunotherapy through a positive modulation of the tumor microenvironment (TME). Antiangiogenetics, in fact, with their inhibitory activity on myelopoiesis that indirectly reduces myeloid-derived suppressor cells (MDSCs) and regulatory T cells’ (Tregs) frequency and function, could have a role in determining an effective anti-tumor immune response. These findings are relevant for the challenges posed to clinicians concerning the clinical impact on treatment strategies for mRCC.

1 July 2019 in Current Opinion in Oncology
Verified
Journal Article
Closed access
FSFlorian Scotté
Florian Scotté
RRRaffaele Ratta
Raffaele Ratta
PBPhilippe Beuzeboc
Philippe Beuzeboc
Purpose of review: Immunotherapeutic strategies have become the new paradigm of cancer care, through their new targeting and safety profile approach, and, de facto, their new monitoring and safety management challenges. Recent findings: Generalities and specificities of the toxicity management related to immune checkpoint inhibitors (ICIs) are highlighted. Predictive factors of safety are issue of research and the challenge of prevention as well as monitoring are huge to alleviate toxicities and enhance safety and efficacy. Particular situations like steroids association and cost-effectiveness approach are summarized. Summary: Patients as well as general practitioners, including health-caregivers, should be informed before ICI initiation of the different alert symptoms which should precede immune-related adverse events.